(Q40687810)

22 September 2017

title

Feasibility of outpatient management of fever in cancer patients with low-risk neutropenia: results of a prospective randomized trial (English)

1 reference

22 September 2017

Malik IA

1

1 reference

22 September 2017

Khan WA

2

1 reference

22 September 2017

Karim M

3

1 reference

22 September 2017

Aziz Z

4

1 reference

22 September 2017

Khan MA

5

1 reference

22 September 2017

language of work or name

English

0 references

publication date

1 March 1995

1 reference

American Journal of Medicine

22 September 2017

published in

1 reference

22 September 2017

volume

98

1 reference

22 September 2017

issue

3

1 reference

22 September 2017

page(s)

224-231

1 reference

Empiric antibacterial therapy in granulocytopenia induced by cancer chemotherapy

22 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980367-2

Infection in cancer patients. A continuing association

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980367-2

Clinical Significance of In Vitro Synergism Between Antibiotics in Gram-Negative Infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980367-2

Antimicrobial Synergism in the Therapy of Gram-Negative Rod Bacteremia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980367-2

Single-drug versus combination empirical therapy for gram-negative bacillary infections in febrile cancer patients with and without granulocytopenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980367-2

Potential of imipenem as single-agent empiric antibiotic therapy of febrile neutropenic patients with cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980367-2

A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980367-2

Intravenous ciprofloxacin as empirical treatment of febrile neutropenic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980367-2

Ceftazidime Monotherapy for Empiric Treatment of Febrile Neutropenic Patients: A Metaanalysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980367-2

Randomised comparison of oral ofloxacin alone with combination of parenteral antibiotics in neutropenic febrile patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980367-2

Origin of infection in acute nonlymphocytic leukemia. Significance of hospital acquisition of potential pathogens.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980367-2

Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980367-2

Quantitative Relationships Between Circulating Leukocytes and Infection in Patients with Acute Leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980367-2

Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980367-2

Cost-effectiveness of outpatient parenteral antibiotics: a review of the literature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980367-2

Piperacillin or ticarcillin plus amikacin. A double-blind prospective comparison of empiric antibiotic therapy for febrile granulocytopenic cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980367-2

Multicenter, randomized trial of ciprofloxacin plus azlocillin versus ceftazidime plus amikacin for empiric treatment of febrile neutropenic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980367-2

Randomized trial comparing ciprofloxacin plus netilmicin versus piperacillin plus netilmicin for empiric treatment of fever in neutropenic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980367-2

Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980367-2

Granulocyte colony-stimulating factor and neutrophil recovery after high-dose chemotherapy and autologous bone marrow transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980367-2

Biologicals and hematopoietic cytokines in prevention or treatment of infections in immunocompromised hosts.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980367-2

Identifying priorities of psychosocial need in cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980367-2

On the receiving end--patient perception of the side-effects of cancer chemotherapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980367-2

Approach to treatment of the febrile cancer patient with low-risk neutropenia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980367-2

Comparative antibacterial activity of new quinolone-carboxylic acid derivatives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980367-2

Efficacy of ofloxacin in experimental Staphylococcus aureus endocarditis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980367-2

Emerging resistance to fluoroquinolones in staphylococci: an alert

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980367-2

Gram-positive infections and the use of vancomycin in 550 episodes of fever and neutropenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980367-2

Empiric use of vancomycin during prolonged treatment-induced granulocytopenia. Randomized, double-blind, placebo-controlled clinical trial in patients with acute leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980367-2

Vancomycin, ticarcillin, and amikacin compared with ticarcillin-clavulanate and amikacin in the empirical treatment of febrile, neutropenic children with cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980367-2

Vancomycin-resistant enterococci

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980367-2

Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980367-2

Gram-positive infections in granulocytopenic patients: an important issue?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980367-2

Outpatient treatment of Hickman catheter infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980367-2

Outpatient treatment of febrile episodes in low-risk neutropenic patients with cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980367-2

Home antibiotic therapy for low-risk cancer patients with fever and neutropenia: a pilot study of 30 patients based on a validated prediction rule

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980367-2

Self-administered antibiotic therapy for chemotherapy-induced, low-risk febrile neutropenia in patients with nonhematologic neoplasms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980367-2

Ceftazidime combined with a short or long course of amikacin for empirical therapy of gram-negative bacteremia in cancer patients with granulocytopenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2899%2980367-2

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0002-9343(99)80367-2

1 reference

release_z37w7tcgafb43bpbph75rzc4ya

22 September 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/z37w7tcgafb43bpbph75rzc4ya

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference